Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Warner-Lambert

Executive Summary

Has filed four NDAs since November 1990. Last December, the firm submitted an NDA for Estrostep, a once-daily triphasic oral contraceptive that combines estrogens in a formula designed to reduce side effects and for Accuretic, an antihypertensive that crosses W-L's ace inhibitor Accupril with the diuretic hydrochlorothiazide. On Feb. 14, the company submitted an NDA for pentostatin, an orphan drug for the treatment of hairy cell leukemia. The company's grand slam filing was completed on Feb. 25, with the submission of Lopid SR, a once-daily version of the cholesterol regulator Lopid.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019064

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel